BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23335114)

  • 1. Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non-small cell lung cancer.
    Harada H; Miyamoto K; Yamashita Y; Nakano K; Taniyama K; Miyata Y; Ohdan H; Okada M
    Cancer; 2013 Feb; 119(4):792-8. PubMed ID: 23335114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylated DLX4 Predicts Response to Pathologic Stage I Non-Small Cell Lung Cancer Resection.
    Harada H; Miyamoto K; Yamashita Y; Taniyama K; Ohdan H; Okada M
    Ann Thorac Surg; 2015 May; 99(5):1746-54. PubMed ID: 25825198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
    Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
    Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation markers and early recurrence in stage I lung cancer.
    Brock MV; Hooker CM; Ota-Machida E; Han Y; Guo M; Ames S; Glöckner S; Piantadosi S; Gabrielson E; Pridham G; Pelosky K; Belinsky SA; Yang SC; Baylin SB; Herman JG
    N Engl J Med; 2008 Mar; 358(11):1118-28. PubMed ID: 18337602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
    Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
    Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
    Kim YT; Lee SH; Sung SW; Kim JH
    Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.
    Chang YS; Wang L; Liu D; Mao L; Hong WK; Khuri FR; Lee HY
    Clin Cancer Res; 2002 Dec; 8(12):3669-75. PubMed ID: 12473575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.
    Bartolucci R; Wei J; Sanchez JJ; Perez-Roca L; Chaib I; Puma F; Farabi R; Mendez P; Roila F; Okamoto T; Taron M; Rosell R
    Clin Lung Cancer; 2009 Jan; 10(1):47-52. PubMed ID: 19289372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients.
    Dietrich D; Hasinger O; Liebenberg V; Field JK; Kristiansen G; Soltermann A
    Diagn Mol Pathol; 2012 Jun; 21(2):93-104. PubMed ID: 22555092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [RUNX3 promoter hypermethylation and prognosis of early surgically resected non-small cell lung cancers].
    Tang Y; Wu F; Hu C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Jul; 36(7):650-4. PubMed ID: 21873791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular predictors of recurrence in stage I non-small cell lung cancer.
    Starnes SL; Pathrose P; Wang J; Succop P; Morris JC; Bridges J; Kupert EY; Anderson M
    Ann Thorac Surg; 2012 May; 93(5):1606-12. PubMed ID: 22440368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome.
    Brabender J; Usadel H; Metzger R; Schneider PM; Park J; Salonga D; Tsao-Wei DD; Groshen S; Lord RV; Takebe N; Schneider S; Hölscher AH; Danenberg KD; Danenberg PV
    Clin Cancer Res; 2003 Jan; 9(1):223-7. PubMed ID: 12538473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
    Zhang Y; Miao Y; Yi J; Wang R; Chen L
    Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
    Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
    Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with recurrence in patients with curatively resected stage I-II lung cancer.
    Koo HK; Jin SM; Lee CH; Lim HJ; Yim JJ; Kim YT; Yang SC; Yoo CG; Han SK; Kim JH; Shim YS; Kim YW
    Lung Cancer; 2011 Aug; 73(2):222-9. PubMed ID: 21168237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TFPI-2 methylation predicts poor prognosis in non-small cell lung cancer.
    Wu D; Xiong L; Wu S; Jiang M; Lian G; Wang M
    Lung Cancer; 2012 Apr; 76(1):106-11. PubMed ID: 21983100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
    Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
    Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of apoptosis-associated speck-like protein containing a CARD gene promoter methylation in resectable non-small-cell lung cancer.
    Zhang Z; Tan S; Zhang L
    Clin Lung Cancer; 2006 Jul; 8(1):62-5. PubMed ID: 16870048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.
    Sung WW; Wang YC; Cheng YW; Lee MC; Yeh KT; Wang L; Wang J; Chen CY; Lee H
    Clin Cancer Res; 2011 Sep; 17(18):5991-9. PubMed ID: 21807637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.